Post-marketing study of cilostazol: Study to Confirm Efficacy in Preventing Recurrent Cerebral Infarction in Comparison with Aspiri
- Conditions
- Patients with cerebral infarction (excluding cardiogenic cerebral embolism)
- Registration Number
- JPRN-C000000129
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 2600
Not provided
(1)Patients with hemorrhage or bleeding tendency (hemophilia, capillary fragility, intracranial hemorrhage, hemorrhage in the digestive tract, hemorrhage in the urinary tract, hemoptysis, and hemorrhage in the vitreous body) (2)Pregnant, possibly pregnant, or nursing women (3)Patients with ischemic heart failure (4)Patients with peptic ulcer (5)Patients with severer blood disorders (6)Patients with severe hepatic or renal (7)Patients with malignant neoplasm or patients who have received any therapy for malignant neoplasm within 5 years prior to entering the study (8)Patients with a history of hypersensitivity to salicylic acid formulations or ingredients of cilostazol tablets (9)Patients with aspirin asthma (asthma attacks induced by nonsteroidal antiinflammatory analgesic agents) or a history of aspirin asthma (10)Patients who are being treated with ticlopidine hydrochloride (11)Patients who are participating in another study for an investigational drug(12)Patients who are otherwise judged inappropriate for inclusion in the study by the investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of cerebral stroke (cerebral infarction, cerebral hemorrhage, or subarachnoid hemorrhage)
- Secondary Outcome Measures
Name Time Method